LFCR
LIFECORE BIOMEDICAL, INC. \DE\
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has 9 SEC Form 4 filings (9 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Jun 8, 2026.
- Industry:Drug Manufacturers - Specialty & Generic
- CEO:Paul Josephs
- Employees:524
- HQ:Chaska, MN, US
- IPO:1996-02-15
No open-market insider trades for LFCR (LIFECORE BIOMEDICAL, INC. \DE\) in the last 365 days.
Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.
Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.
Related companies
LIFECORE BIOMEDICAL, INC. \DE\ is in the Healthcare sector.